Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1201657-32-0

Post Buying Request

1201657-32-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • Ethyl 2-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazol-1-yl)propanoate

    Cas No: 1201657-32-0

  • No Data

  • No Data

  • No Data

  • SAGECHEM LIMITED
  • Contact Supplier
  • ETHYL 2-METHYL-2-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-1H-PYRAZOL-1-YL)PROPANOATE

    Cas No: 1201657-32-0

  • No Data

  • No Data

  • No Data

  • coolpharm Ltd
  • Contact Supplier
  • 1-(1-Ethoxycarbonyl-2,2-dimethyl)-1H-pyrazole-4-boronic acid, pinacol ester

    Cas No: 1201657-32-0

  • No Data

  • No Data

  • No Data

  • NovaChemistry
  • Contact Supplier

1201657-32-0 Usage

Uses

Ethyl 2-Methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanoate is used as a reactant in the preparation of inhibitors that overcome the G1202R anaplastic lymphoma kinase resistance mutation.

Check Digit Verification of cas no

The CAS Registry Mumber 1201657-32-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,1,6,5 and 7 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1201657-32:
(9*1)+(8*2)+(7*0)+(6*1)+(5*6)+(4*5)+(3*7)+(2*3)+(1*2)=110
110 % 10 = 0
So 1201657-32-0 is a valid CAS Registry Number.

1201657-32-0Relevant articles and documents

Carbon-14 radiolabelling and tissue distribution evaluation of a potential anti-TB compound

Sonopo, Molahlehi S.,Venter, Kobus,Winks, Susan,Marjanovic-Painter, Biljana,Morgans, Garreth L.,Zeevaart, Jan R.

, p. 264 - 269 (2016)

This paper describes a five-step synthesis of a carbon-14-labelled pyrazole compound (11). A total of 2.96 MBq of 11 was obtained with the specific activity of 2242.4 MBq/mmol. The radiochemical purity was >99%, and the overall radiochemical yield was 60% based on the [14C6] 4-bromoaniline starting material. Biodistribution results showed that the radiotracer (administrated orally) has a high accumulation in the small intestine, large intestine and liver of both non-infected and tuberculosis (TB)-infected mice. Therefore, this suggests that compound 11 undergoes hepatobiliary clearance. The compound under investigation has been found to be slowly released from the liver between 2 and 8 h. The study revealed that 11 has no affinity for TB cells.

FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE

-

Paragraph 00209, (2020/03/23)

The present invention relates to a fused tricyclic compound and application thereof in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B. Specifically, the present invention relates to a compound having Formula (I) or

DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF

-

Paragraph 0213; 0220, (2016/08/23)

The present invention discloses a novel DGAT1 inhibitor, especially the compound of formula (I) or a pharmaceutically acceptable salt thereof, preparation and pharmaceutical composition thereof, as well as their uses in the preparation of a medicament for the prevention and treatment of Familial hyperchylomicronemia (FCS), obesity, hyperlipoproteinemia or hypertriglyceridemia.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1201657-32-0